{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T07:19:35Z","timestamp":1693379975456},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"j_med-2017-0058_s_005_w2aab2b8d175b1b7b1aab1c15b1Aa\"><jats:title>Background<\/jats:title><jats:p>Therapeutic options for thymoma-associated myasthenia gravis (MG) patients complicated with hypertension and\/or diabetes post thymectomy are often conventional steroids. As the prevalence of diabetes and hypertension globally increases, other therapeutic options for these patients are of great importance.<\/jats:p><\/jats:sec><jats:sec id=\"j_med-2017-0058_s_006_w2aab2b8d175b1b7b1aab1c15b2Aa\"><jats:title>Material\/methods<\/jats:title><jats:p>9 patients with thymoma-associated MG complicated with hypertension and\/or diabetes after thymectomy were administered 75 mg\/m2 of docetaxel and 70 mg\/m2 of cisplatin on day 1. The treatment could be repeated at 3-week intervals, ranging from 1 to 4 cycles according to the status of the patients. Therapeutic efficacy and side effects were evaluated.<\/jats:p><\/jats:sec><jats:sec id=\"j_med-2017-0058_s_007_w2aab2b8d175b1b7b1aab1c15b3Aa\"><jats:title>Results<\/jats:title><jats:p>2 patients were complicated with type 2 diabetes, 6 with hypertension, and 1 with both diabetes and hypertension. After docetaxel\/cisplain therapy, the MG symptoms were markedly improved in all patients (2, complete remission; 3, basic remission; 3, marked improvement; 1, improvement). Acetylcholine receptor (AchR) antibody levels were decreased in 8 patients. Minor adverse effects were observed in 2 patients, 1 with Grade II gastrointestinal reaction, and the other with pulmonary infection.<\/jats:p><\/jats:sec><jats:sec id=\"j_med-2017-0058_s_008_w2aab2b8d175b1b7b1aab1c15b4Aa\"><jats:title>Conclusion<\/jats:title><jats:p>Docetaxel plus cisplatin might be an effective therapeutic option for thymoma-associated MG patients complicated with hypertension \/diabetes post thymectomy without worsening thymoma and hypertension \/ diabetes.<\/jats:p><\/jats:sec>","DOI":"10.1515\/med-2017-0058","type":"journal-article","created":{"date-parts":[[2017,12,3]],"date-time":"2017-12-03T22:17:29Z","timestamp":1512339449000},"page":"403-408","source":"Crossref","is-referenced-by-count":3,"title":["Docetaxel\/cisplatin therapy in myasthenia gravis with hypertension\/diabetes"],"prefix":"10.1515","volume":"12","author":[{"given":"Guoyan","family":"Qi","sequence":"first","affiliation":[{"name":"No. 9 Fangbei Road, Chang\u2019an District, Shijiangzhuang 050011 , Hebei Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinping","family":"Xue","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang , Shijiazhuang 050011 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhao","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang , Shijiazhuang 050011 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang , Shijiazhuang 050011 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang , Shijiazhuang 050011 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"key":"2022042708270229415_j_med-2017-0058_ref_001_w2aab2b8d175b1b7b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Gilhus NE and Verschuuren JJ: Myasthenia gravis: subgroup classification and therapeutic strategies. The Lancet Neurology 2015; 14: 1023-1036","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"2022042708270229415_j_med-2017-0058_ref_002_w2aab2b8d175b1b7b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A and Strobel P: The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmunity reviews 2013; 12: 875-884","DOI":"10.1016\/j.autrev.2013.03.007"},{"key":"2022042708270229415_j_med-2017-0058_ref_003_w2aab2b8d175b1b7b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Li Z-Y: China guidelines for the diagnosis and treatment of myasthenia gravis. Neuroimmunology and Neuroinflammation 2016; 3: 1-9","DOI":"10.20517\/2347-8659.2015.60"},{"key":"2022042708270229415_j_med-2017-0058_ref_004_w2aab2b8d175b1b7b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Palace J, Newsom-Davis J and Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50: 1778-1783","DOI":"10.1212\/WNL.50.6.1778"},{"key":"2022042708270229415_j_med-2017-0058_ref_005_w2aab2b8d175b1b7b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Hossain P, Kawar B and El Nahas M: Obesity and diabetes in the developing world--a growing challenge. The New England journal of medicine 2007; 356: 213-215","DOI":"10.1056\/NEJMp068177"},{"key":"2022042708270229415_j_med-2017-0058_ref_006_w2aab2b8d175b1b7b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Gao Y, Chen G, Tian H, Lin L, Lu J, Weng J, et al: Prevalence of hypertension in china: a cross-sectional study. PloS one 2013; 8: e65938","DOI":"10.1371\/journal.pone.0065938"},{"key":"2022042708270229415_j_med-2017-0058_ref_007_w2aab2b8d175b1b7b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Qi G, Liu P, Dong H, Gu S, Yang H and Xue Y: Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma. The Tohoku journal of experimental medicine 2017; 241: 281-286","DOI":"10.1620\/tjem.241.281"},{"key":"2022042708270229415_j_med-2017-0058_ref_008_w2aab2b8d175b1b7b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Rosai J and Sobin L: World Health Organization International histological classification of tumors: histological typing of tumors of the thymus. 1999;","DOI":"10.1007\/978-3-642-60157-6"},{"key":"2022042708270229415_j_med-2017-0058_ref_009_w2aab2b8d175b1b7b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-2492","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R"},{"key":"2022042708270229415_j_med-2017-0058_ref_010_w2aab2b8d175b1b7b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Li Z-Y, Bogdos M, Giannopoulos S, Kosmidou M, Mittelbronn M and Qi X-K: China guidelines for the diagnosis and treatment of myasthenia gravis. Neuroimmunol Neuroinfammation 2016; 3: 1-9","DOI":"10.20517\/2347-8659.2015.60"},{"key":"2022042708270229415_j_med-2017-0058_ref_011_w2aab2b8d175b1b7b1ab2b2c11Aa","unstructured":"Osserman KE and Genkins G: Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. The Mount Sinai journal of medicine, New York 1971; 38: 497"},{"key":"2022042708270229415_j_med-2017-0058_ref_012_w2aab2b8d175b1b7b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2001; 12: 47-51","DOI":"10.1023\/A:1008328501128"},{"key":"2022042708270229415_j_med-2017-0058_ref_013_w2aab2b8d175b1b7b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Park S, Ahn M-j, Ahn JS, Sun J-M, Shim YM, Kim J, et al: A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors. J Thorac Oncol 2013; 8: 959-966","DOI":"10.1097\/JTO.0b013e318292c41e"},{"key":"2022042708270229415_j_med-2017-0058_ref_014_w2aab2b8d175b1b7b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Roka S, Kornek G, Sch\u00fcller J, Ortmann E, Feichtinger J and Armbruster C: Carcinoma showing thymic-like elements\u2013a rare malignancy of the thyroid gland. Br J Surg 2004; 91: 142-145","DOI":"10.1002\/bjs.4510"},{"key":"2022042708270229415_j_med-2017-0058_ref_015_w2aab2b8d175b1b7b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Liu G-C, Gao B-L, Yang H-Q, Qi G-Y and Liu P: The clinical absolute and relative scoring system\u2013A quantitative scale measuring myasthenia gravis severity and outcome used in the traditional Chinese medicine. Complement Ther Med 2014; 22: 877-886","DOI":"10.1016\/j.ctim.2014.08.003"},{"key":"2022042708270229415_j_med-2017-0058_ref_016_w2aab2b8d175b1b7b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Qi G, Liu P, Dong H, Gu S, Yang H and Xue Y: Metastatic Thymoma-Associated Myasthenia Gravis: Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent. Medical science monitor : international medical journal of experimental and clinical research 2017; 23: 1217-1223","DOI":"10.12659\/MSM.902442"},{"key":"2022042708270229415_j_med-2017-0058_ref_017_w2aab2b8d175b1b7b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Yeh JH, Chen HJ, Lin CC, Chen YK, Chiu HC and Kao CH: Risk of diabetes mellitus among patients with myasthenia gravis. Acta neurologica Scandinavica 2015; 132: 132-138","DOI":"10.1111\/ane.12374"},{"key":"2022042708270229415_j_med-2017-0058_ref_018_w2aab2b8d175b1b7b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Huang J, Rizk NP, Travis WD, Riely GJ, Park BJ, Bains MS, et al: Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg 2009; 138: 26-31","DOI":"10.1016\/j.jtcvs.2009.03.033"},{"key":"2022042708270229415_j_med-2017-0058_ref_019_w2aab2b8d175b1b7b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Drachman DB, Adams RN, Hu R, Jones RJ and Brodsky RA: Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Annals of the New York Academy of Sciences 2008; 1132: 305-314","DOI":"10.1196\/annals.1405.033"},{"key":"2022042708270229415_j_med-2017-0058_ref_020_w2aab2b8d175b1b7b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Drachman DB, Jones RJ and Brodsky RA: Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide. Annals of neurology 2003; 53: 29-34","DOI":"10.1002\/ana.10400"},{"key":"2022042708270229415_j_med-2017-0058_ref_021_w2aab2b8d175b1b7b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Albany C and Sonpavde G: Docetaxel for the treatment of bladder cancer. Expert Opin Investig Drugs 2015; 24: 1657-1664","DOI":"10.1517\/13543784.2015.1109626"},{"key":"2022042708270229415_j_med-2017-0058_ref_022_w2aab2b8d175b1b7b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Betticher DC, Schmitz S-FH, T\u00f6tsch M, Hansen E, Joss C, von Briel C, et al: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non\u2013small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 2003; 21: 1752-1759","DOI":"10.1200\/JCO.2003.11.040"},{"key":"2022042708270229415_j_med-2017-0058_ref_023_w2aab2b8d175b1b7b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Ridwelski K, Gebauer T, Fahlke J, Kr\u00f6ning H, Kettner E, Meyer F, et al: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47-51","DOI":"10.1023\/A:1008328501128"},{"key":"2022042708270229415_j_med-2017-0058_ref_024_w2aab2b8d175b1b7b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128","DOI":"10.1016\/S1470-2045(09)70364-X"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/med\/12\/1\/article-p403.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2017-0058\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2017-0058\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T16:21:41Z","timestamp":1693326101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2017-0058\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,9,6]]},"published-print":{"date-parts":[[2017,9,6]]}},"alternative-id":["10.1515\/med-2017-0058"],"URL":"https:\/\/doi.org\/10.1515\/med-2017-0058","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,1]]}}}